Antiallergic agents (A61P37/08)

A   Human necessities(305254)
A61P37/08                     Antiallergic agents (antiasthmatic agents a61p0011060000; ophthalmic antiallergics a61p0027140000)(324)
ethod for production of pharmaceutical composition with fexofenadine, providing anti-allergic and anti-inflammatory effect // 2614961
FIELD: pharmacy.SUBSTANCE: pharmaceutical composition for fexofenadine gel preparation contains the following auxiliary components: thickener - Carbopol, neutralizing agent - sodium hydroxide 5% solution, glycerin and purified water. First, a hydrophilic base is prepared - carbopol is mixed with glycerol at a ratio of 1:20, with vigorous stirring, purified water is added, and the resulting system is stirred until complete homogenization, fexofenadine is then dissolved in 5% sodium hydroxide solution, the resulting fexofenadine alkaline solution is gradually added to the hydrophilic base with vigorous stirring to obtain a gel composition with a pH of 6.5. The gel is stored at a temperature of 15÷25°C for 2 years, if an increased storage life of the gel composition is required, nipagin or benzalkonium chloride is introduced.EFFECT: fexofenadine gel has a high therapeutic efficacy with minimal side effects, and low cost.1 tbl, 4 ex

Stable pharmaceutical composition for oral administration comprising levocetirizine, or pharmaceutically acceptable salt thereof and montelukast or pharmaceutically acceptable salt thereof // 2614382
FIELD: medicine, pharmacy.SUBSTANCE: this present invention relfers to a pharmaceutical composition in the form of a capsule for oral administration for asthma or allergic rhinitis prevention or treatment. The composition comprises: (a) the first fraction of particles in the form of mini-pill comprising levocetirizine, or pharmaceutically acceptable salt thereof and organic acid; and (b) the second fraction of particles in the form of mini-pill comprising montelukast or pharmaceutically acceptable salt thereof. The organic acid is citric acid, tartaric acid, succinic acid or ascorbic acid. The organic acid is present in the amount of 100 parts by weight per 100 parts of levocetirizine. The said first and second particle fractions are physically separated and filled into the capsule. A method for pharmaceutical capsule composition production is also described. The pharmaceutical composition of this invention inhibits the production of related contaminants of levocetirizine and montelukast and provides good stability.EFFECT: invention expands the product range of drugs for allergic rhinitis or asthma prevention or treatment.9 cl, 3 dwg, 4 tbl, 6 ex

ilk-based protein hydrolysates and infant nutritional compositions prepared from them // 2612008
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and concerns composition for oral tolerance stimulation in babies or subjects requiring it, containing milk-based protein hydrolysate, obtained by processing solution of milk-based protein material with at least one trypsin-like endopeptidase, obtained from microorganism Kutzneria albida, and at least one chymotrypsin-like endopeptidase, obtained from microorganism Nocardiopsis SP. or Metarhizium anisopliae. Group of inventions also concerns composition for reducing risk of allergy in babies or subjects requiring it, containing milk-based protein hydrolysate; composition for reducing severity or frequency of allergy in infants or in next period of life in babies or subjects requiring it, containing milk-based protein hydrolysate.EFFECT: group of inventions provides production of hydrolysates, which have low residual antigenicity and low allergenicity.9 cl, 1 ex, 3 dwg, 1 tbl
ethod of increasing efficiency of therapy of autoimmune diseases, such as rheumatoid arthritis // 2611341
FIELD: pharmaceutics.SUBSTANCE: group of inventions is disclosed to reduce undesirable reaction of immunosuppressive drugs for treating autoimmune diseases. There are presented: pharmaceutical composition containing iguratimod or its salt and one or more immunosuppressive agents selected from nucleic acid synthesis inhibitors (e.g., methotrexate) or steroid anti-inflammatory drugs (e.g., prednisolone), device and kit of above purpose.EFFECT: technical result consists in reduction of hepatocellular damage and elimination of reticulocytopenia caused by said immunosuppressants.12 cl, 5 tbl, 9 ex

New allergen // 2608494
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology, namely to novel horse allergens, and can be used in medicine for prophylactic or therapeutic treatment or diagnostics of type I allergy in horses. Horse allergen is obtained, which represents secretoglobin with molecular weight of 15 kDa in non-reducing conditions and contains first peptide chain with molecular weight of approximately 5 kDa and second peptide chain with molecular weight of approximately 10 kDa, linked to each other. Recombinant form of said allergen is also obtained.EFFECT: invention enables to obtain recombinant horse allergen with completely determined amino acid sequence.13 cl, 10 dwg, 3 tbl, 8 ex

odification of group 6 poaceae (bluegrass) allergens with low allergenic capacity due to mutagenesis of proline residues // 2607373
FIELD: biotechnology.SUBSTANCE: present invention relates to biotechnology, namely to recombinant modifications of group 6 Poaceae (bluegrass) allergens, and can be used in medicine for preventing or treating type 1 allergies, in initiation of which group 6 bluegrass allergens are involved. Recombinant allergen Phl p 6 is obtained, in which prolines, corresponding in linearized form to prolines in positions 29, 30, 57 and 79 of amino acid sequence of wild type protein Phl p 6 in compliance with SEQ ID NO: 2, are mutated separately or in combination by point mutations, selected from deletions and substitutions of amino acids.EFFECT: present invention enables to obtain recombinant allergen Phl p 6 with low IgE reactivity, compared to existing non-mutated allergens, and with substantially preserved T-lymphocytes reactivity at the same time.12 cl, 20 dwg, 2 tbl, 3 ex

Purified extract separated from pseudolysimachion rotundum var subintegrum with high content of active ingredient, its production and composition containing the above extract as an active ingredient to prevent or treat inflammation, allergies and asthma // 2606768
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, namely, to the purified extract, broken up using butanol (ATS1) from the Pseudolysimachion rotundum var subintegrum extract. Purified extract broken up using butanol (ATS1) from the Pseudolysimachion rotundum var subintegrum extract, for the prevention and treatment of inflammatory diseases, received in accordance with the method comprising: addition of ethanol to the dried Pseudolysimachion rotundum var subintegrum and carrying out the extraction with cold water; further carrying out the extraction with hot water under reflux with the receipt of the 1st extract at the 1st stage; suspending of said 1st extract in water, adding butanol to said extract, fractionation with obtaining a water layer and butanol layer and the collection of butanol layer with the receipt of purified extract, broken up using butanol (ATS1), under certain conditions, wherein obtain a extract containing verprozid, veratric acid, katalpozid, pikrozid II, izovanilloilkatalpol and 6-O-veratroilkatalpol in certain proportions (versions). A pharmaceutical composition. Functional food product.EFFECT: above described extract Pseudolysimachion rotundum var subintegrum has increased anti-inflammatory effect.4 cl, 15 dwg, 10 tbl, 8 ex

Derivatives of 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indole-acetic acid and use thereof as prostaglandin d2 receptor modulators // 2596823
FIELD: chemistry.SUBSTANCE: invention relates to derivatives of 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indole-acetic acid with formula (I) or pharmaceutically acceptable salt of such compound, where R1 and R2 represent independently of each other hydrogen, (C1-C4)alkyl, (C1-C4)alkoxy group, halogen, trifluoromethoxy group or trifluoromethyl; R3 represents hydrogen, (C1-C4)alkyl, (C1-C2)alkoxy-(C2-C3)alkyl, (C1-C4)fluoroalkyl or (C3-C6)cycloalkyl-(C1-C2)alkyl; and R4 represents heteroaryl group, which is unsubstituted or mono-substituted, where substitutes are independently selected from group comprising halogen, (C1-C4)alkyl, (C3-C6)cycloalkyl, (C1-C4)alkoxy group, (C1-C4)fluoroalkyl and phenyl; where term "heteroaryl" denotes 5-10-member monocyclic or bicyclic aromatic ring containing one nitrogen atom and optionally one additional heteroatom selected from oxygen, nitrogen and sulphur. Invention also relates to the pharmaceutical composition based on compound with formula (I) and application of compound with formula (I).EFFECT: obtaining new heterocyclic compounds having antagonistic activity in relation to CRTH2 receptor.17 cl, 19 dwg, 51 ex

Food composition with probiotics // 2595396
FIELD: food industry.SUBSTANCE: disclosed is use of baby food for production of a nutritional composition for baby feeding. Baby food contains from 5 to 16 en% protein, from 30 to 60 en% fat, from 25 to 75 en% carbohydrates, as well as Bifidobacterium breve and Lactobacillus paracasei.EFFECT: invention provides higher level of Bifidobacteria and Lactobacilli in feces in infants and control of their population in intestine at level of types to values close to values observed in breastfed children.13 cl, 1 dwg, 4 tbl, 10 ex

Pharmaceutical product containing extract(s) of allergen tongs and method for production thereof // 2593778
FIELD: medicine. SUBSTANCE: invention refers to medicine, particularly to pharmaceutical product containing extract of allergen, which contains at least one extract bodies mites and extract faecal particles tongs, where pharmaceutical product is quickly decomposing sublingual tablet for treating and/or preventing allergies or allergic asthma. Method of producing allergen mites involves the following steps: selecting fractions bodies mites and/or fractions faecal particles mites; optional combination of several fractions; extraction of allergens fraction bodies mites and/or fractions faecal particles mites; determination of concentration of allergen group 1 and 2; mixing one or more extracts bodies tongs with one or more extracts faecal particles mites. EFFECT: invention implementation allows to produce pharmaceutical product containing extract of allergen tongs with controlled ratio of allergen group 1 to allergen Group 2. 17 cl, 4 tbl, 1 dwg, 7 ex

Allergens produced by recombinant methods // 2592674
FIELD: biotechnology. SUBSTANCE: present invention relates to biotechnology, specifically to novel dog allergens, and can be used in medicine. Allergen Can f 4 is produced by recombinant method. Obtained allergen can be used during in vitro diagnosing or treating allergy, caused by dandruff or dogs wool. EFFECT: present invention enables to obtain allergen Can f 4 by recombinant method with completely determined amino acid sequence. 11 cl, 10 dwg, 5 tbl, 1 ex

Selective glycosidase inhibitors and use thereof // 2592285
FIELD: chemistry. SUBSTANCE: invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, where each R represents H; R1 and R2 are independently selected from a group consisting of H, C1-6alkyl, C2-6alkenyl, C1-6alkoxy and -(CH2)n-cyclopropyl, where n equals 1 or 2; or R1 and R2 can be bonded together with a nitrogen atom to which they are bonded to form azetidine, pyrrolidine or isoxazolidine, where said C1-6alkyl is optionally substituted by fluorine or hydroxy; R3 is selected from a group consisting of C1-8alkyl, C2-8alkenyl, C3-6cycloalkyl, phenyl and pyridine, each optionally substituted with 1-3 substitutes selected from fluorine and OH; R4 is selected from a group consisting of H, F or C1-8alkyl; or R3 and R4 and a carbon atom to which they are bonded, can be combined together to form vinyl or 3-7-membered carbocyclic ring, wherein said 3-7-member carbocyclic ring optionally contains a double bond; and R5 is selected from H, F and OH; provided that when R4 represents F while R5 is other than OH. Invention also relates to specific derivatives of pirano[3,2d]thiazole. Disclosed compounds are intended for producing a pharmaceutical composition possessing inhibitory activity on O-GlcNAcase, containing an active ingredient in an effective amount of compound or its pharmaceutically acceptable salt in combination with pharmaceutically acceptable carrier. EFFECT: technical result is a compound for selective inhibition of glycosidase. 15 cl, 1 tbl, 218 ex
ixture of indigestible oligosaccharides to stimulate immune system // 2591831
FIELD: food industry.SUBSTANCE: group of inventions relates to food industry, specifically to a nutritional composition, which is not human milk and contains fucosyllactose and betagalactooligosaccharide having structure [galactose]n-glucose, where n equals a whole number from 2 to 60, and have more than 80 % of beta-1,4 and beta-1,6 links; and to use of said composition to provide nourishment children, elderly and patients with cancer and/or patients infected by HIV, as well as for treating and/or preventing development of viral infections, immune diseases and/or disease which can be prevented and/or cured by amplification of Th1 response and/or Th1/Th2 balance, and for enhancing response to vaccination.EFFECT: group of inventions provides a synergetic effect on boosting Th1 response.14 cl, 3 ex, 1 tbl

Pharmaceutical composition for oral administration with improved solubility and/or absorbability // 2589701
FIELD: pharmaceutics.SUBSTANCE: present invention relates to a pharmaceutical composition for oral administration containing 4-((1-methyl pyrrole-2-yl)carbonyl)-N-(4-(4-morpholine-1-yl-carbonylpiperidin-1-yl)phenyl)-1-piperazincarboxamide, its salt or solvate as active pharmaceutical ingredient and fumaric acid as acid additive. Fumaric acid is contained in an amount of 0.25 to 5 weight fractions on the weight ratio of 4-((1-methyl pyrrole-2-yl)carbonyl)-N-(4-(4-morpholine-1-yl-carbonylpiperidin-1-yl)phenyl)-1-piperazincarboxamid.EFFECT: also described is method of stabilization, improve solubility and improved intestinal absorption of 4-((1-methyl pyrrole-2-yl)carbonyl)-N-(4-(4-morpholine-1-yl-carbonylpiperidin-1-yl)phenyl)-1-piperazincarboxamide by adding of fumaric acid to pharmaceutical composition.12 cl, 5 dwg, 8 tbl, 9 ex

ethods of treating allergic diseases // 2587061
FIELD: medicine.SUBSTANCE: present invention relates to a method of treating allergic diseases by administering a therapeutically effective amount of a benzo[b]azepine TLR8 receptor agonist VTX-378 - (1E,4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide or a pharmaceutically acceptable salt thereof. Said benzo[b]azepine VTX-378 is administered intranasally in a dosage form containing a single dose of 25 mcg to 1,000 mcg. Administration is daily, three times a week (intermittently), twice a week, once a week, every 14 days, once a month or once every 6-8 weeks.EFFECT: treatment with benzo[b]azepine VTX-378 significantly reduced allergic reaction in an experimental model of allergic rhinitis, sensitised with ragweed pollen allergen, and showed an increase in volume of nasal cavity.19 cl, 14 dwg, 2 tbl, 3 ex

Pyruvamide compounds as inhibitors of allergen dust mites 1 group, which is peptidase, and use thereof // 2586215
FIELD: pharmaceuticals.SUBSTANCE: invention relates to the field of medicinal compounds. Proposed is pyruvate-amide compounds of formula (X), which inhibit the allergen is dust mite group 1, which is a peptidase, e.g., Der p 1, Der f 1, Eur m 1.EFFECT: also provided are pharmaceutical compositions comprising said compounds and use of said compounds and compositions for inhibiting allergen 1 group is a peptidase dust mites, and for the treatment of diseases and disorders mediated by allergen dust mite group 1, in particular asthma, rhinitis, allergic conjunctivitis, atopic dermatitis, allergic condition caused by dust mite allergic condition caused by dust mite allergen group 1 and atopy in dogs.51 cl, 3 dwg, 1 tbl, 1 ex

Versions of group of 5 allergens of true grasses with reduced allergenicity resulting from mutagenesis of proline residues // 2575606
FIELD: chemistry.SUBSTANCE: invention relates to field of biochemistry, in particular to hypoallergenic polypeptide of Grass family. Also disclosed are DNA molecule, which codes said hypoallergenic polypeptide, recombinant expression vector, containing said DNA molecule, and host cell, transformed by means of said DNA molecule or said vector, for obtaining said hypoallergenic polypeptide. Disclosed are method for obtaining said hypoallergenic polypeptide, application of said hypoallergenic polypeptide or said DNA molecule for obtaining medication and pharmaceutical preparation for prevention or treatment of type 1 allergies, which contains efficient quantity of hypoallergenic polypeptide.EFFECT: invention makes it possible to efficiently treat type 1 allergies.14 cl, 8 tbl, 9 ex, 24 dwg

Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists // 2573828
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to new aminoalkylpyrimidine derivatives of formula (I) or their pharmaceutically acceptable salts exhibiting the properties of histamine H4 receptor antagonists. The compounds are applicable in respiratory diseases, including asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD); ophthalmic diseases, including conjunctivitis, dry eye syndrome, cataract; dermatological diseases, including eczema, dermatitis (e.g., atopic dermatitis), psoriasis, urticaria, pemphigus, dermatitis herpetiformis, cutaneous vasculitis, itch; inflammatory intestinal diseases, including nonspecific ulcerative colitis, Crohn's disease; and autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, cutaneous lupus, systemic lupus erythematosus, widespread vasculitis and graft rejection. In formula IR1 and R2 form together with N atom to which they are bound, a saturated heterocyclic group containing one nitrogen atom and free frpm any other heteroatoms; the above heterocyclic group is substituted by one -NRaRb group and optionally substituted by one or more C1-4alkyl groups; wherein the heterocyclic group represents a 4-7-merous monocyclic group; Ra represents H or C1-4alkyl; Rb represents H or C1-4alkyl; R3 represents H or C1-8alkyl; R4 represents a) C1-8alkyl optionally substituted by one or more halogens; b) C3-10cycloalkyl-C0-4alkyl; c) aryl-C0-4alkyl or d) 5-6-merous heteroaryl-C0-4alkyl, wherein the radicals b), c) or d) may be substituted as specified in the patent claim; n equals to 1 or 2; each R5 independently represents H or C1-8alkyl.EFFECT: compounds can find application in treating or preventing an allergic, immune system or inflammatory disease, pain or cancer.22 cl, 18 ex

Phenyloxadiazole derivatives as pgds inhibitors // 2572608
FIELD: chemistry.SUBSTANCE: invention relates to compounds of formula (I), where R1 is hydrogen or C1-C6alkyl; R2 is hydrogen and R3 is hydroxy(C1-C6)alkyl; or pharmaceutically acceptable salts thereof. The invention also relates to methods of producing compounds of formula (I), intermediate compounds given in paragraphs 14-19 of the claim, and a method of producing an intermediate compound according to paragraph 17 of the claim.EFFECT: obtaining compounds of formula as PGD2 synthase inhibitors and intermediate compounds for production thereof.20 cl, 3 ex

ethod of obtaining allergen extract // 2572230
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and are intended for treatment of allergy. To obtain allergen extract contact of initial material with liquid extraction means with obtaining mixture is realised. Mixture is subjected to first degree of separation. Contact of residue of initial material with means for extraction of allergens is performed. Mixture is subjected to second stage of separation with obtaining raw extract of allergen, from which low-molecular fraction is removed. The procedure is repeated until allergen extract has conductivity lower than 1000 mcSm/cm at 3-5°C with obtaining purified native allergen extract. Acidification to pH 2-4 is carried out. Then, low-molecular fraction is removed and pH is brought to 7-8 with obtaining depigmented allergen extract. Contact with glutaraldehyde is realised. Molecules with molecular size smaller than 100 kDa are removed. The procedure is repeated until allergen extract has conductivity lower than 210 mcSm/cm at 3-5°C and/or glutaraldehyde is absent. Allergen extract is a component of composition and vaccine for allergy treatment.EFFECT: application of group of inventions makes it possible to obtain allergen, possessing reduced ability to bind IgE and suitable for immunotherapy.26 cl, 10 dwg, 11 tbl, 8 ex

Composition for interleukine-4 cytokine gene silencing // 2563989
FIELD: medicine.SUBSTANCE: invention concerns a composition for the interleukin-4 cytokine gene silencing by means of an RNA interference mechanism, consisting of a cationic LTP peptide dendrimer described by formula (Arg)8(Lys)4(Lys)2Lys-Ala-Cys-NH2 used as a carrier, and two siRNA molecules described by formulas 5-UUGAUGAUCUCCUGUAAGGtt-3 and 5-AAAGAUGUCUGUUACGGUCtt-3.EFFECT: creating the low-toxic composition used for interleukin-4 gene silencing.3 cl, 18 dwg, 14 tbl, 4 ex

Fexofenadine microcapsules and compositions containing thereof // 2563623
FIELD: medicine, pharmaceutics.SUBSTANCE: claimed invention relates to field of pharmaceutics and represents pharmaceutical composition, containing water-suspendable combined granulate of microcapsules with immediate release and inactive ingredients, where said microcapsules are microcapsules with disguised taste and represent fexofenadine, covered with water-insoluble polymer coating; as well as method for obtaining said composition and method for treating inflammation-associated condition, including introduction of said composition to patient.EFFECT: realisation of invention provides improved disguise of fexofenadine taste along with immediate release of active ingredient.22 cl, 65 tbl, 28 dwg

Novel crystalline forms of 4,4'-[4-fluoro-7({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl} ethynyl)-2-methyl-1h-indole-1,3-diiyl]dibutanoic acid, 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl} ethynyl)-1h-indole-1,3-diiyl]dibutanoic acid and 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl) butoxy]phenyl} ethynyl)-1h-indole-1,3-diiyl]dibutanoic acid // 2560147
FIELD: chemistry.SUBSTANCE: invention relates to novel crystalline forms of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diiyl]dibutanoic acid, 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diiyl]dibutanoic acid and 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diiyl]dibutanoic acid.EFFECT: obtaining novel compounds.18 cl, 16 dwg, 7 tbl, 24 ex

Indole derivative and its pharmaceutical application // 2556216
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to compound, represented by the following formula , or its pharmaceutically acceptable salt. In claimed formula each symbol has values, determined in formula of invention. Versions of formula [I] compound and particular compounds are also objects of invention. In addition, invention relates to pharmaceutical composition, ITK inhibitor and means for treatment or prevention of inflammatory diseases, allergic diseases, autoimmune diseases, transplant rejection and other diseases and methods of treating said diseases.EFFECT: claimed compounds inhibit induced T-cellular kinase (ITK).32 cl, 86 tbl, 387 ex

Antiallergic agent // 2553354
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry and represents an anti-allergic agent containing polysaccharide containing galactose, glucose and rhamnose as ingredients, wherein polysaccharide contains galactose, glucose and rhamnose in molar ratio 3-5:1-3:1, and polysaccharide has certain structure.EFFECT: invention provides extending the range of antiallergic agents.12 cl, 6 ex, 6 dwg, 1 tbl

Pharmaceutical composition, containing derivatives of glutarimides, and their application for treatment of eosinophilic diseases // 2552929
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to pharmaceutics. A medication represents derivatives of glutarimides of the general formula (I) or their pharmaceutically acceptable salts. The invention also relates to pharmaceutical compositions and a method of treatment.EFFECT: ensured by the application of non-toxic derivatives of the said glutarimides for the treatment of eosinophilic diseases, mainly of an allergic origin.16 cl, 12 tbl, 7 ex

Dosage form containing desloratadine and method for producing it // 2550958
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, particularly to pharmaceutical industry, and describes a tabletted oral dosage form containing desloratadine in an amount of 3 to 15%, processing additives and a pharmaceutically acceptable excipient. The processing additives consist of sodium croscarmellose, magnesium stearate and povidone. The excipient represents a mixture of lactose disaccharide and microcrystalline cellulose polysaccharide in ratio from 2:1 to 8:1. Lactose and microcrystalline cellulose have an average particle size from 30 to 200 mcm. Producing the table involves granulating desloratadine, lactose and microcrystalline cellulose.EFFECT: invention provides reducing granulate compression force, increasing process capability and maintaining the high quality of the tablets.9 cl, 4 tbl, 4 ex

Allergotropines for treatment of allergy caused by house dust mites // 2548727
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to the field of medicine, namely to immunology and allergology, and can be used for the treatment of allergy to house dust mites. For this purpose an allergotropine is obtained by a method of chemical conjugation of an allergoid and synthetic highly molecular immunomodulator Polyoxidonium. The allergotropine contains 1000±200 PNU of the allergoid of house dust mites Dermatophagoides pteronyssinus or Dermatophagoides farinae and 6.25±1.25 mg of Polyoxidonium.EFFECT: obtaining the allergotropines, based on the allergoid forms of allergens of house dust mites Dermatophagoides pteronyssinus or Dermatophagoides farinae, possessing more expressed immunogenic and hyposensitising properties in comparison with the native allergen, makes it possible to carry out the effective treatment of allergy by ASIT method.2 ex, 2 tbl, 2 dwg
Food compositions containing punicalagins // 2542497
FIELD: pharmacology.SUBSTANCE: invention mainly relates to a food composition, including punicalagins.EFFECT: improved action in respect to health improvement.8 cl, 1 tbl, 1 ex

Nutritional composition containing strains bifidobacterium longum and relieving symptoms of food allergy, especially in infants and children // 2539514
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to microbiology. What is presented is using the strain Bifidobacterium longum NCC 2705 (CNCM-I2618) for preparing a complete nutrient composition used for relieving symptoms of allergy to food in the patients suffering allergies caused by ingestant allergens.EFFECT: composition provides the secondary prevention of allergic reactions caused by the above ingestant allergens.16 cl, 7 dwg, 1 ex

Complex preparation based on allergens of birch pollen and muramylpeptides // 2537225
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to complex injection preparation for treating polynoses by ASIT method. Said preparation is obtained by simple mixing birch pollen allergoid and muramylpeptide without carrying out chemical conjugation of components, with 2 mg of muramylpeptide being added per 1000 PNU dose.EFFECT: invention provides considerable enhancement of immune response and stimulates high level of production of specific IgG-antibodies, as well as makes it possible to reduce course of treatment of polynoses, which reduces possibility of complications.1 dwg, 2 tbl

Composition for reducing injury caused by uv radiation // 2537187
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to field of pharmaceutics and represents composition for reducing injury caused by ultraviolet radiation, which includes one or more compounds selected from the group consisting of D-methionine and its salts.EFFECT: invention provides creation of stable and safe composition, which can be applied daily.10 cl, 37 ex, 7 dwg

Pharmaceutical composition containing desloratadine (versions) // 2537169
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry and medicine, namely to manufacturing drug preparations for treating allergic diseases, such as allergic rhinitis and urticaria. According to the first version, the pharmaceutical composition contains an active substance that is desloratadine, and additives, including citric acid, calcium hydrogen phosphate dihydrate, microcrystalline cellulose, starch, lactose, magnesium stearate, and talc. According to the second version, the pharmaceutical composition contains an active substance that is desloratadine, and additives, including Pearlitol 100SD-Mannitol, calcium hydrogen phosphate dihydrate, microcrystalline cellulose, starch, magnesium stearate, and talc. According to the third version, the pharmaceutical composition contains an active substance that is desloratadine, and additives, including sodium carboxymethyl starch, microcrystalline cellulose, colloidal silicone dioxide, and sodium sodium stearyl fumarate. According to the fourth version, the pharmaceutical composition contains an active substance that is desloratadine, and additives, including sodium carboxymethyl starch, microcrystalline cellulose, Pearlitol 100SD-Mannitol, magnesium stearate, and talc. The pharmaceutical composition is presented in the form of a film-coated tablet.EFFECT: pharmaceutical composition according to the invention is storage-stable and releases the active substance quickly in the gastrointestinal tract.10 cl, 9 tbl, 20 ex

Nutritional composition containing apple extract and reducing food allergy symptoms, especially in children // 2536916
FIELD: food industry.SUBSTANCE: invention relates to nutritional compositions based on a natural extract. One proposes the application of an apple extract containing polyphenols for the manufacture of a complete nutritional composition for the reduction of symptoms of allergy caused by food in patients suffering from allergy caused by food allergens. The apple extract is enriched with polyphenols by at least 1.5 times relative to the unpurified apple extract. The composition contains 0.1% - 1 wt % of the apple extract.EFFECT: proposed composition has no effect on the patients` sensitisation to the said allergens.13 cl, 6 dwg
Composition containing bacterial waste products useful for human body // 2535152
FIELD: biotechnology.SUBSTANCE: invention is a composition having antibacterial, immunostimulating, anti-allergic and anti-inflammatory action, containing bacterial waste products useful for human body, in the form of exometabolites and fermentolysis products, characterised in that it is a culture medium of lactic acid bacteria, containing laxarane in an amount of 5-10 g/ml, caseicyne, isracydine or their mixture and lectins in an amount of 0.05-2.5 mol/l, histamine in an amount of 0.8-2.0 mmol/l and monocarboxylic fatty acid with an unbranched chain, namely, acetic acid, propionic acid, butyric acid and valeric acid - in an amount of 10-20 mg/ml.EFFECT: expanding the range of agents having complementary antibacterial, immunomodulating, anti-allergic and anti-inflammatory action.4 cl, 5 ex

Antioxidant composition // 2535099
FIELD: chemistry.SUBSTANCE: invention relates to the field of cosmetology. Described is a stable and safe antioxidant composition, which can be applied daily. In particular, described is the antioxidant composition, which contains one or more compounds, selected from the group, which consists of D-aspartic acid, its derivatives and/or its salts. The composition can be applied with the purpose of suppressing and/or relief of a skin condition. Conditions of skin can include, but are not limited by them, small wrinkles, rough skin, dry skin, skin cancer, skin allergy, skin inflammation, and light-sensitive dermatosis. The composition can be applied as a medication for the external application on the skin.EFFECT: invention ensures an increase of the antioxidant effect of the composition.4 cl, 5 dwg, 31 ex
ethod of treating allergic diseases // 2531100
FIELD: medicine.SUBSTANCE: enterosorbent is administered in the morning in an S daily dose on an empty stomach daily for 1-3 months 2-3 hours before meals. Colonising the intestinal flora with a normal flora is ensured by daily 4-week roal administration of the liquid biocomplex Normoflorin 3 times a day in age doses; the first and second intakes involve the preparation Normoflorin L, and the third one - Normoflorin B.EFFECT: effective treatment of allergic diseases by eliminating endogenous and exogenous toxic substances of various nature and reducing thereby body sensibilisation, providing extensive cleansing of the bowels from fermentation and putrifaction products, pathogenic and opportunistic flora, and ensuring natural immunity stimulation.1 ex

Hypoallergenic dermatological composition // 2526833
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to chemical-pharmaceutical industry and deals with application of extract of above-ground part/parts of oats, excluding grains, containing from 2 to 15% of flavonoids and from 0.2 to 2% of A and B avenacosides, for preparation of cosmetic and dermatological composition.EFFECT: invention represents dermatological and cosmetic composition, containing such extract and possessing hypoallergenic properties.8 cl, 2 ex, 2 tbl, 3 dwg

Prevention and treatment of allergic diarrhoea // 2522240
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to the pharmaceutical industry and represents application of a composition, containing Bifidobacterium breve CNCM I-3865 (NCC2950) for preparation of a composition for prevention of allergic diarrhoea.EFFECT: invention provides extension of an arsenal of means for prevention of allergic diarrhea.7 cl, 1 dwg

Treatment of dermatological allergic states // 2521357
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to chemical-pharmaceutical industry, particularly to method of treatment of dermatological allergic state. Proposed method comprises injection of efficient amount of [4-(5-aminomethyl-2-fluorophenyl)piperidine-1-silt][7-fluorine-1-(2-metoxyethyl)-4-trifluorometoxy-1H-indol-3-il]methanon or its appropriate N-oxide, pharmaceutically acceptable salt or solvate.EFFECT: higher efficiency.5 cl, 1 ex, 1 tbl

Low-molecular polysulphated hyaluronic acid derivative and medicinal agent containing same // 2519781
FIELD: chemistry.SUBSTANCE: invention relates to an agent for preventing and/or treating an allergic disease selected from pollinosis, allergic rhinitis, allergic conjunctivitis, atopic dermatitis and asthma, which is a low-molecular polysulphated hyaluronic acid derivative.EFFECT: obtaining a low-molecular polysulphated hyaluronic acid derivative.15 cl, 103 dwg, 17 tbl, 55 ex

Therapeutic agent for treating rhinitis // 2502519
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutics and medicine and concerns preparing a fast-acting effective and safe agent for treating rhinitis. Solving the problem provides the agent for treating rhinitis, particularly allergi rhinitis containing C-type natriuretic peptide (CNP) and/or B-type natriuretic peptide (BNP) as an active ingredient.EFFECT: invention provides the notable health improvement in rhinitis, particularly in allergic rhinitis, and besides, the therapeutic effect, ensures fast and prolonged action, and gives no local side effects.21 cl, 7 ex, 7 tbl
ethod for prevention of using corticosteroids // 2500408
FIELD: medicine, pharmaceutics.SUBSTANCE: what is presented is using a composition containing galactooligosaccharide, fructooligosaccharide and uronic acid oligosaccharide in preparing a composition for oral administration into an infant for preventing the local administration of corticosteroids and/or preventing the administration of a calcineurin inhibitor into the above infant, wherein uronic acid oligosaccharide represents a pectin degradation product and/or an alginate degradation product, and wherein using the corticosteroids and/or administering the calcineurin inhibitor is applicable for treating eczema, infantile eczema, atopic dermatitis, dermatitis herpetiformis, contact dermatitis, seborrheic dermatitis, neurodermatitis, psoriasis and intertrigo. Particularly, the composition is a nutritional composition.EFFECT: what is shown is reducing probability of the local administration of corticosteroids and dermatological preparations to be required for the purpose of preventing the above skin diseases, or reducing the length of using the corticosteroids.5 cl, 2 ex

Naphthalene carboxamide derivatives as protein kinase and histone deacetylase inhibitors, methods for preparing and using them // 2497809
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to naphthalene carboxamide derivatives of general formula I which possess the properties of protein kinase or histone deacetylase inhibitors. The compounds can find application for preparing a drug for treating inflammatory diseases, autoimmune diseases, oncological disease, diseases of the nervous system and neurodegenerative diseases, allergies, asthma, cardiovascular diseases and metabolic diseases or disease related to hormonal diseases. In general formula I: , Z represents CH or N; each of the groups R1, R2 and R3 represents hydrogen, halogen, alkyl, alkoxy or trifluoromethyl; R4 represents or X represents a benzene ring or a pyridine ring; R5 represents one or more substitutes specified in a group consisting of hydrogen, halogen, alkyl, alkoxy or trifluoromethyl. The invention also refers to a method for preparing the above compounds, a pharmaceutical preparation and using them.EFFECT: preparing the compounds which possess the properties of protein kinase or histone deacetylase inhibitors.13 cl, 10 tbl, 6 dwg

Biologically active complex possessing anti-allergic action // 2493861
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry and represents a complex of biologically active substance for treating allergic diseases of various genesis, characterised by the fact that it has been recovered from cod liver oil by gradual fractionation from ballast lipids by extraction in a two-phase oil and water extractant, centrifugation and ultrafiltration or diafiltration through a material with separation limit 25 kDa, and contains peptides 30-55%, amino acids 40-65%, carbohydrates 2-8%, micro and macroelements 2-13%.EFFECT: invention provides the drug spectrum broadening.8 ex, 3 tbl

2,4-pyrimidine diamine compounds and use thereof // 2493150
FIELD: chemistry.SUBSTANCE: invention relates to novel of 2,4-pyrimidine diamine compounds of formula I, which inhibit degranulation of immune cells and can be used in treating cell reactions mediated by FcεRI or FcγRl receptors. In formula (I) each R2 and R4 is independently phenyl substituted with one or more R8 groups or a heteroaryl selected from a group consisting of , where the heteroaryl is optionally substituted with one or more R8 groups and at least one of R2 and R4 is a heteroaryl; R5 is selected from a group consisting of (C1-C6)alkyl, optionally substituted with one or more identical or different R8 groups, -ORd, -SRd, fluorine, (C1-C3)halogenalkyloxy, (C1-C3)perhalogenalkyloxy, -NRcRc, (C1-C3)halogenalkyl, -CN, -NO2, -C(O)Rd, -C(O)ORd, -C(O)NRcRc, -C(NH)NRcRc, -OC(O)Rd, -OC(O)ORd, -OC(O)NRcRc; -OC(NH)NRcRc, - [NHC(O)]nORd, R35 is hydrogen or R8; each Y is independently selected from a group consisting of O, S and NH; each Y1 is independently selected from a group consisting of O, S and NH; each Y2 is independently selected from a group consisting of CH, CH2, S, N, NH and NR37. Other values of radicals are given in the claim.EFFECT: improved efficiency.19 cl, 6 tbl.

2-s-benzylsubstituted pyrimidines as crth2 antagonists // 2491279
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to new 2-S-benzylpyrimidine derivatives having CRTH2 receptor antagonist activity. In formula 1: R1 means -CO2H; R4a and R4b mean hydrogen; W means -C(O)NR7-; R2 and R3, each independently mean F; Cl; Br;-NR10R11 or (C1-C6)alkoxy, optionally substituted by 1-3 halogen atoms; R5 means hydrogen; R6 means (C1-C6)alkyl; (C6-C19)aryl or (5-15)-member heteroaryl containing nitrogen, oxygen or sulphur atoms as heteroatoms, wherein above aryl and heteroaryl are optionally substituted by one or more substitutes specified in a group consisting of halogen; (C1-C6)alkyl optionally substituted by 1-3 halogen atoms; and (C1-C6)alkoxy optionally substituted by one, two or three halogen atoms; R7 means hydrogen; R10 and R11, each independently mean (C1-C6)alkyl; or R10 and R11, together with N, whereto attached form a 3-8- member saturated or unsaturated ring optionally containing one or more O or S atoms, or one or more additional N atoms in the ring; k is equal to 0; m is equal to 1.EFFECT: invention also refers to using the above compounds for preparing a drug for treating allergic and inflammatory diseases mediated by CRTH2 receptor activity, such as asthma, atopic dermatitis, allergic conjunctivitis, Churg-Strauss disease, sinusitits, basophilic leukaemia, and recurrent urticaria.27 cl

Antibody preparation // 2491094
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to biotechnology and immunology. The preparation contains an antibody, histidine and Polysorbate 80. Besides, a method of treating a subject with using the above preparation and a method of stabilising anti-human α-interferon antibody 13H5 are described. The invention can be used in medicine.EFFECT: what is disclosed is a stable aqueous preparation containing the antibody or fragment thereof which are specifically bound to human α-interferon.7 cl, 3 tbl, 2 ex
Use of oligosaccharides containing n-acetyllactosamine for eliciting immune responses in newborns // 2486904
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to medicine, namely to paediatrics and may be used for preparing a drug or therapeutic nutritional composition for maturating an immune responses in a newborn infant. That is ensured by using an oligosaccharide specified in a group consisting of: lacto-N-tetrose, lacto-N-neotetrose, lacto-N-hexose, lacto-N-neohexose, para-lacto-N-hexose, para-lacto-N-neohexose, lacto-N-octose, lacto-N-neooctose, iso-lacto-N-octose, para-lacto-N-octose and lacto-N-decose. Also, the above oligosaccharide may be used for modulating the immune system of the newborn infant to ensure the developing beneficial intestinal microflora for the first weeks of life comparable to such found in breastfed infants.EFFECT: group of inventions enables the developing beneficial intestinal microflora in the infant, and reduces the risk of a further allergy.27 cl, 1 ex

ethod of loading dendritic cells with antigen of infectious origin opistorchis felineus // 2486238
FIELD: biotechnology.SUBSTANCE: monocytes are isolated from venous blood MNCs using the Percoll cushion bi-gradient of density: 47.5% SIP and 15% SIP, respectively, at cooling to +4°C. The monocytes are placed in a completely nutritional culture medium with adding 20 ng/ml IL-4 and 20 ng/ml GM-CSF. The completely nutritional culture medium is replaced on the day 3 of cultivation. On the day 4 of cultivation the antigen of infectious origin Opisthorchis felineus is added at a dose of 40 mcg/ml and maturation of dendritic cells is simultaneously induced with lipopolysaccharide E.coli of serotype 055: B5 in a dose of 1 mcg/ml. On the day 6 of cultivation the dendritic cells are washed and analysed.EFFECT: use of the method provides obtaining the mature, antigen-loaded dendritic cells.2 dwg
 
2550913.
Up!